首页 News 正文

On January 26, the information released by the National Drug Administration (NMPA) showed that Smeaglutide Tablets under Novo Nordisk (China) Pharmaceutical Co., Ltd. was approved for listing to treat type 2 diabetes. This is the first domestically approved oral GLP-1 (glucagon like peptide-1) receptor agonist.
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

阿豆学长长ov 注册会员
  • 粉丝

    0

  • 关注

    0

  • 主题

    27